Literature DB >> 27731647

Hit-to-Lead Optimization of Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists with a Diphenylmethane-Scaffold: Design, Synthesis, and Biological Study.

Grazia Chiellini1, Giulia Nesi2, Simona Sestito2, Sara Chiarugi2, Massimiliano Runfola2, Stefano Espinoza3, Martina Sabatini1, Lorenza Bellusci1, Annunziatina Laurino4, Elena Cichero5, Raul R Gainetdinov6,7, Paola Fossa5, Laura Raimondi4, Riccardo Zucchi1, Simona Rapposelli2.   

Abstract

The trace amine-associated receptor 1 (TAAR1) is a G-protein-coupled receptors (GPCR) potently activated by a variety of molecules besides trace amines (TAs), including thyroid hormone-derivatives like 3-iodothyronamine (T1AM), catechol-O-methyltransferase products like 3-methoxytyramine, and amphetamine-related compounds. Accordingly, TAAR1 is considered a promising target for medicinal development. To gain more insights into TAAR1 physiological functions and validation of its therapeutic potential, we recently developed a new class of thyronamine-like derivatives. Among them compound SG2 showed high affinity and potent agonist activity at mouse TAAR1. In the present work, we describe design, synthesis, and SAR study of a new series of compounds (1-16) obtained by introducing specific structural changes at key points of our lead compound SG2 skeleton. Five of the newly synthesized compounds displayed mTAAR1 agonist activity higher than both SG2 and T1AM. Selected diphenylmethane analogues, namely 1 and 2, showed potent functional activity in in vitro and in vivo models.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27731647     DOI: 10.1021/acs.jmedchem.6b01092

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Substrate switchable Suzuki-Miyaura coupling for benzyl ester vs. benzyl halide.

Authors:  Masato Ohsumi; Akitaka Ito; Nagatoshi Nishiwaki
Journal:  RSC Adv       Date:  2018-10-12       Impact factor: 4.036

2.  New Insights into the Potential Roles of 3-Iodothyronamine (T1AM) and Newly Developed Thyronamine-Like TAAR1 Agonists in Neuroprotection.

Authors:  Lorenza Bellusci; Annunziatina Laurino; Martina Sabatini; Simona Sestito; Paola Lenzi; Laura Raimondi; Simona Rapposelli; Francesca Biagioni; Francesco Fornai; Alessandra Salvetti; Leonardo Rossi; Riccardo Zucchi; Grazia Chiellini
Journal:  Front Pharmacol       Date:  2017-12-12       Impact factor: 5.810

Review 3.  The Case for TAAR1 as a Modulator of Central Nervous System Function.

Authors:  Grazia Rutigliano; Alice Accorroni; Riccardo Zucchi
Journal:  Front Pharmacol       Date:  2018-01-10       Impact factor: 5.810

Review 4.  3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?

Authors:  Grazia Rutigliano; Lavinia Bandini; Simona Sestito; Grazia Chiellini
Journal:  Int J Mol Sci       Date:  2020-03-15       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.